Artificial hearts have reshaped not just cardiology but the way societies think about life, death, and the boundaries of the human body. Since the first permanent total artificial heart was implanted in Barney Clark in 1982, the technology has been used in more than 1,700 patients as a bridge to transplantation, yet a device suitable for permanent, lifelong use remains elusive after six decades of research.1PubMed. The ongoing quest for the first total artificial heart as destination therapy The ripple effects of that quest extend far beyond the operating room, touching transplant policy, family life, health-care economics, racial equity, and even the philosophical question of what it means to be alive.
From Experimental Surgery to a Clinical Lifeline
When Barney Clark received the Jarvik-7 heart at the University of Utah, the event triggered intense media coverage and public debate over the ethics, cost, and wisdom of replacing a human heart with a machine.2Oxford Academic (JHMI / Europe PMC). Don B. Olsen. True Valor: Barney Clark and the Utah Artificial Heart Clark survived 112 days. The experiment was widely seen as a medical milestone, but the complications he endured and his ultimate death also raised hard questions about whether the technology was ready for patients. Those questions have never fully gone away.
In the decades since, the primary clinical role of the total artificial heart has been as a bridge to transplantation. Patients whose hearts are failing so severely that no partial device can keep them alive receive the machine to buy time until a donor heart becomes available. By 2013, one major device alone had been implanted in more than a thousand patients worldwide in that bridging role.3The Journal of Heart and Lung Transplantation. Safety and feasibility of total artificial heart as destination therapy The number has continued to climb, and newer devices are in advanced trials. Early data from the Aeson total artificial heart, for instance, show a six-month survival rate around 90 percent in critically ill patients with cardiogenic shock, though full results from its pivotal trial are expected in 2025.4PubMed Central. The total artificial heart: An existential transformation beyond technology
What the technology has not yet achieved is true destination therapy, meaning a permanent replacement for the human heart in patients who will never receive a transplant. High complication rates, bulky hardware, limited durability, and poor biocompatibility remain major barriers.1PubMed. The ongoing quest for the first total artificial heart as destination therapy The gap between “keeping someone alive long enough to get a transplant” and “replacing a transplant altogether” is where much of the technology’s societal tension lives.
How Transplant Waiting Lists Changed
Artificial hearts and related mechanical support devices have fundamentally altered the organ allocation landscape. Because these devices can sustain a patient for weeks or months, they changed the calculus of who gets listed for a transplant and how urgently. In the United States, a 2018 change to the donor heart allocation policy gave higher priority to patients on certain mechanical support devices. The impact was dramatic: median time on the waiting list for patients on biventricular support dropped from 88 days before the policy change to 22 days afterward, and the share of those patients who ultimately received a transplant rose from 65 percent to 85 percent.5PubMed. Impact of 2018 Donor Heart Allocation Policy Change on Patients on Biventricular Support: A UNOS Database Analysis Both waitlist survival and post-transplant survival improved after the change.
This is a genuine public-health success, but it carries a downstream effect: as patients on mechanical support get prioritized, those without devices may wait longer, or face a system that increasingly assumes mechanical bridging is part of the standard pathway. That assumption only works if the devices are accessible to everyone, and as we will see, they are not.
What Life Looks Like on a Mechanical Heart
Living with a total artificial heart is nothing like living with a healthy heart. Patients depend on an external pneumatic driver connected through tubes that exit the body, which means they are tethered to a machine around the clock. Despite that constraint, rehabilitation can produce meaningful functional gains. In one retrospective study, patients who underwent postsurgical rehabilitation improved their functional mobility scores by roughly 48 percent and their daily activity scores by about 40 percent by the time they were discharged.6Cardiopulmonary Physical Therapy Journal. Total Artificial Heart: A Retrospective Descriptive Analysis of Functional Improvement Associated With Postsurgical Rehabilitation A separate case report found that a standard cardiac rehabilitation program produced improvements in walking distance and self-reported quality of life over just two weeks, comparable to improvements typically seen over longer periods following a transplant.7Journal of Cardiopulmonary Rehabilitation and Prevention. Prehabilitation Using a Cardiac Rehabilitation Program for a Patient With a Total Artificial Heart Prior to Heart Transplantation
These gains matter enormously because patients who arrive at transplant in better physical condition tend to recover faster afterward. The artificial heart, paradoxically, can make the transplant itself go more smoothly by giving the patient time and support to rebuild strength. But the device still imposes severe lifestyle limitations. Patients cannot shower normally, travel easily, or be far from a specialized center. The low quality of life imposed by current hardware is one of the reasons destination therapy remains out of reach.1PubMed. The ongoing quest for the first total artificial heart as destination therapy
The Burden on Families and Caregivers
A detail that rarely makes the headlines is what happens to the people around the patient. Mechanical heart devices require constant vigilance: monitoring for infection at the driveline exit site, managing alarms, troubleshooting equipment. That work falls largely on family caregivers, and the evidence consistently shows that the burden is significant.
A systematic review of qualitative and quantitative studies on caregivers of patients with left ventricular assist devices found that caregiver strain peaked between one and three months after implantation, with caregivers reporting considerable stress in meeting both their own needs and those of their loved one.8PubMed Central. Left Ventricular Assist Device Caregiver Experiences and Health Outcomes: A Systematic Review of Qualitative and Quantitative Studies A separate study found that strain worsened sharply in the first month, then gradually returned to pre-implantation levels by about six months, though there was a twist: patients who had the worst symptoms before surgery tended to show the greatest quality-of-life improvement, while their caregivers experienced worsening strain.9PubMed Central. Patient and Caregiver Determinants of Patient Quality of Life and Caregiver Strain in Left Ventricular Assist Device Therapy That mismatch is a reminder that the device can simultaneously improve the patient’s life and make the caregiver’s harder.
For pediatric patients the picture is even more complicated. A multi-center study found that caregiver worry and difficulty balancing demands were the most common family-centered issues early after implantation and did not fade quickly. As time went on, more caregivers reported financial stress, sibling stress, and family conflict compared to the initial post-implant period.10PubMed Central. Patient and Parent Reported Outcomes in Pediatric Ventricular Assist Device Support: A Multi-Center ACTION Learning Network Feasibility and Pilot Experience When a child is on a mechanical heart, the entire household reorganizes around the device, and siblings often bear the cost of that shift in attention and resources.
Who Gets Access and Who Does Not
Artificial hearts and ventricular assist devices are expensive, technically demanding, and available only at specialized centers. Those facts create stark disparities. An analysis of national data found that among patients with the type of heart failure these devices treat, rates of both device implantation and heart transplantation were 25 percent lower for Black men and 46 percent lower for transplant specifically, compared to white men.11PubMed Central. Disparities by Sex, Race, and Ethnicity in Use of Left Ventricular Assist Devices and Heart Transplants Among Patients With Heart Failure With Reduced Ejection Fraction Women also had lower rates of access.
An earlier study zeroed in on the factors behind those gaps. Being over 65, being female, being Black, being admitted to a non-academic hospital, and living in certain geographic regions all independently reduced the odds of receiving a device.12PubMed. Disparities in access to left ventricular assist device therapy The non-academic hospital finding is especially telling: if you are treated at a community hospital that does not have a mechanical support program, the technology effectively does not exist for you. Your doctor may not even raise it as an option.
These disparities mirror broader patterns in advanced cardiac care, but artificial hearts magnify them. The devices require not just surgical expertise but a dedicated support infrastructure: a team to manage the equipment, a rehabilitation program, caregivers who can handle the at-home responsibilities, and often proximity to the implanting center for follow-up. Patients without stable housing, reliable transportation, or a strong caregiver network can be screened out before they are ever offered the device. The result is a technology that benefits patients with means disproportionately, even in systems with universal insurance coverage.
The Economic Scale of Mechanical Hearts
The financial implications were anticipated early. A projection from the mid-1980s estimated that the total cost of a left ventricular assist device, its implantation, and maintenance over an expected four and a half years of survival could reach about $150,000 in 1983 dollars, and the gross annual cost to society could fall between $2.5 billion and $5 billion.13PubMed. Artificial heart and assist devices: directions, needs, costs, societal and ethical issues Adjusted for inflation, those numbers have only grown, and modern devices with their associated hospitalizations, readmissions, and outpatient management have made mechanical circulatory support one of the most resource-intensive areas in all of medicine.
For hospitals, running a mechanical heart program is a strategic investment. It attracts patients who need high-acuity care, drives transplant volumes, and builds institutional reputation. But it also requires enormous infrastructure spending. For insurers and health systems, the question is whether the cost per quality-adjusted year of life gained is justifiable compared to other uses of the same resources. That question gets particularly uncomfortable when destination therapy is on the table: a patient on a permanent mechanical heart will need device-related care for the rest of their life, with no transplant to eventually simplify the picture.
Redefining Death and the Ethics of Deactivation
Perhaps the most profound societal impact of the artificial heart is how it destabilizes longstanding definitions of death. When a patient’s biological heart has been removed and replaced with a machine, what does “cardiac death” mean? If the device is pumping oxygenated blood while the brain has irreversibly ceased to function, is the patient dead? And if a patient with a functioning artificial heart asks that the device be turned off, is honoring that request closer to withdrawing life support or to causing death?
These are not hypothetical questions. One widely discussed case involved a patient with decision-making capacity who requested deactivation of a total artificial heart. Although there is a well-established legal and ethical consensus that patients have the right to refuse or withdraw life-sustaining treatment, that consensus developed before mechanical heart devices were common and is not uniformly accepted in these cases.14PubMed. Challenges in deactivating a total artificial heart for a patient with capacity For a ventilator or dialysis machine, the principle is broadly accepted: the treatment supports a failing body, and the patient can choose to stop. But turning off a total artificial heart is different because the biological heart is gone. There is no underlying organ to “fail” once the device stops; instead the machine is functionally the heart. Clinicians, ethicists, and legal experts continue to wrestle with whether deactivation in this context constitutes withdrawal of treatment or something else entirely.
On a broader philosophical level, the artificial heart disrupts the cultural association between the heartbeat and life itself. As one analysis frames it, what does it mean to die for a patient on mechanical support when a machine continues to circulate oxygenated blood? Does death require the deliberate act of deactivating the machine? Is “technological death” truly death?15European Journal of Heart Failure. The Total Artificial Heart: An Existential Transformation Beyond Technology These are not questions medicine alone can answer. They spill into law, religion, and culture, and they will become more pressing as artificial hearts improve and are implanted in larger numbers of patients.
Living with a Machine Inside You
Beyond the clinical and policy dimensions, there is a deeply personal question about what it feels like to live with an artificial heart. The human heart occupies an outsized place in how people think about identity, emotion, and selfhood. We speak of heartbreak, courage as having heart, and love as something felt in the chest. When that organ is replaced by a mechanical pump, the symbolic framework shifts.
Scholars who study the experience of living with artificial organs have identified two conflicting effects. On one hand, the device can reinforce a view of the body as machine-like and separable from the self, as if the person is merely a consciousness piloting biological hardware that can be swapped out piece by piece. On the other hand, the device produces real changes to subjective experience, such as the loss of a heartbeat, altered sensations in the chest, and dependence on external equipment, that patients describe as changes to who they are, not just to what their body does.16HASTINGS CENT REP. A Heart without Life: Artificial Organs and the Lived Body Some patients with continuous-flow devices have no pulse at all. For those individuals, the absence of a heartbeat is not a metaphor for lifelessness; it is a daily, felt reality that challenges how they relate to their own body.
Religious and theological perspectives add another layer. Traditions that regard the heart as the seat of the soul or the center of spiritual life must reconcile those beliefs with a patient whose heart is a titanium-and-plastic pump. Some scholars have explored whether the bodily incorporation of mechanical devices crosses a boundary of what is “natural,” while others argue that restoring health through technology is consistent with religious values of stewardship and healing. These conversations remain active in bioethics literature and faith communities alike.
Engineering the Untethered Future
One of the most anticipated developments is the elimination of the driveline, the tube that currently passes through the skin to connect the implanted device to its external power source. That tube is a constant infection risk and the single biggest limitation on patient independence. Researchers have been working on transcutaneous energy transfer systems that can power an implanted heart wirelessly through the skin.17PubMed. Transcutaneous Energy Transmission System for a Totally Implantable Artificial Heart Using a Two-Wire Archimedean Spiral Coil If these systems can be made reliable and efficient enough for clinical use, the result would be a fully implantable artificial heart with no external components visible or vulnerable to infection.
That leap, from a device that tethers the patient to one that disappears entirely inside the body, would change almost every societal dimension discussed above. It would reduce the caregiver burden, lower infection-related hospital readmissions, improve quality of life to the point where destination therapy becomes realistic, and potentially open the technology to a wider population of patients. It would also sharpen the philosophical questions: when the device is invisible and the patient looks and feels healthy, the boundary between “person with a heart” and “person with a machine” becomes harder to draw from the outside.
More than 90 patients worldwide have now received the Aeson total artificial heart, with over 60 implanted since the program restarted in 2022, and a pivotal French trial is collecting data that could help determine whether newer designs can serve as a true bridge toward long-term or permanent support.4PubMed Central. The total artificial heart: An existential transformation beyond technology Whether the next generation of devices will finally close the gap between bridging and permanent therapy is uncertain, but the societal infrastructure, the ethics frameworks, the allocation policies, the caregiver support systems, and the equity debates, is already being built around the assumption that they will.